Overcoming Immunogenicity Challenges of AAV Gene Therapy Vectors

Time: 2:30 pm
day: Track A - Day 1 PM


  • AAV gene therapy elicits a complex immune response, involving innate and adaptive B and T cell responses that can affect safety, efficacy and the ability to re-dose AAV vectors
  • Pre-existing anti-AAV neutralizing antibodies preclude many patients from being able to receive AAV gene therapy
  • I will present unpublished data from studies in mice, nonhuman primates and humans using our ImmTOR tolerogenic nanoparticle to mitigate de novo AAV immunogenicity as
    well as data on a novel and differentiated IgG protease to address pre-existing antibodies